Dr. John H. Sampson, M.D., Ph.D. has joined the Immunomic Therapeutics Inc. scientific advisory board.
Sampson, who is also chair of the department of neurosurgery at Duke University, will advise on scientific and technical matters relating to brain tumors as the company pursues application of its investigational LAMP-Vax platform technology in oncology.
He will also advise new research combining LAMP technology and a cytomegalovirus immunotherapy platform, recently announced in a licensing agreement between Immunomic and Annias Immunotherapeutics that aims to support and accelerate development of a potential new generation of cancer immunotherapy.
Currently, the phase II trial, called ATTAC-II (NCT02465268), is recruiting participants with newly-diagnosed glioblastoma.
Information in Movers and Shakers is provided by the submitter. To submit a Movers and Shakers item, visit https://thedailyrecord.com/movers/.